Low-dose buprenorphine infusion to prevent postoperative hyperalgesia in patients undergoing major lung surgery and remifentanil infusion. a double-blind, randomized, active-controlled trial
Background. Postoperative secondary hyperalgesia arises from central sensitization due to pain pathways facilitation and/
or acute opioid exposure. The latter is also known as opioid-induced hyperalgesia (OIH). Remifentanil, a potent l-opioid agonist,
reportedly induces postoperative hyperalgesia and increases postoperative pain scores and opioid consumption. The
pathophysiology underlying secondary hyperalgesia involves N-methyl-D-aspartate (NMDA)-mediated pain pathways. In